7 unchanged sentences
The following table summarizes information with respect to the purchase of our common stock during the three months ended December 31, 2020.
−Removed: Publicly Announced Program (1)
−Removed: Period Total Number of Shares Purchased Average Price Paid Per Share Total Number of Shares Repurchased Total Dollar Amount Purchased Maximum Dollar Value of Shares that May Yet be Purchased
+Added: Period Total Number of Shares Purchased Average Price Paid Per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)
October 1-31, 2020 — $ — — $ 467,615,810
1 unchanged sentence
December 1-31, 2020 637,656 $ 71.53 637,656 $ 412,017,195
−Removed: Total Q4 2019 — $ — — $ — $ 389,537,445
+Added: Total 783,442 783,442
_______________
(1) On February 28, 2020, our Board of Directors authorized the repurchase of up to $500.0 million of our common stock.
−Removed: On November 1, 2018, our Board of Directors approved the authorization for the repurchase of up to an additional $350 million of our outstanding common stock.
−Removed: The repurchase program does not include a specific timetable or price targets and may be suspended or terminated at any time.
−Removed: Shares may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of prevailing market conditions and other factors.
+Added: We currently do not have any specific timetable or price targets for repurchasing shares, and may suspend or terminate the program at any time.
+Added: Shares may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market prevailing conditions and other factors.
+Added: Shares may be purchased through open market or privately negotiated transactions at the discretion of management based on its evaluation of market prevailing conditions and other factors.
Stock Performance Graph
−Removed: The following table and graph present the cumulative total stockholder return for Ingevity's common stock compared with the Standard & Poor's (S&P) MidCap 400 Index, S&P SmallCap 600 Index and the Dow Jones (DJ) U.S.
+Added: The following table and graph present the cumulative total stockholder return for Ingevity's common stock compared with the Standard & Poor's (S&P) MidCap 400 Index and the Dow Jones (DJ) U.S.
Specialty Chemicals Index since Ingevity's stock began "regular-way" trading on the NYSE on May 16, 2016.
−Removed: The graph assumes the investment of $100 in each of Ingevity's common stock, the S&P MidCap 400 Index, S&P SmallCap 600 Index, and DJ U.S.
+Added: The graph assumes the investment of $100 in each of Ingevity's common stock, the S&P MidCap 400 Index, and DJ U.S.
Specialty Chemicals Index on May 16, 2016, and that all dividends, if any, were reinvested.
−Removed: Previously, Ingevity was included in the S&P SmallCap 600 Index and was moved to the S&P MidCap 400 Index on March 12, 2019, so we updated our comparative broad market index accordingly for the fiscal year ended December 31, 2019.
−Removed: In light of our market capitalization, the S&P MidCap 400 index is a more comparable broad market index with which to compare Ingevity.
May 16, 2016 2016 2017 2018 2019 2020
Ingevity Corporation $ 100.00 $ 204.24 $ 262.36 $ 311.58 $ 325.32 $ 281.94
−Removed: S&P SmallCap 600 Index 100.00 123.53 139.77 127.87 156.94
S&P MidCap 400 Index 100.00 115.37 134.09 119.22 150.41 170.94
−Removed: Dow Jones US Specialty Chemicals Index $ 100.00 $ 105.60 $ 129.24 $ 120.40 $ 135.15
+Added: Dow Jones U.S.
+Added: Specialty Chemicals Index $ 100.00 $ 105.60 $ 129.24 $ 120.40 $ 135.15 $ 155.70
The graph and related information set forth above are not deemed to be "filed" with the SEC for purposes of Section 18 of the Exchange Act or incorporated by reference into any future filing made by us with the SEC, except to the extent that we specifically incorporate it by reference into any such filing.
1 unchanged sentence
SELECTED FINANCIAL DATA
−Removed: Ingevity did not operate as a separate, stand-alone entity for all five years listed below.
−Removed: Our consolidated balance sheets as of December 31, 2019, 2018, 2017, and 2016, respectively, and our consolidated statement of operations, comprehensive income (loss), and cash flows for the years ended December 31, 2019, 2018, and 2017, respectively, consist of the consolidated balances of Ingevity as prepared on a stand-alone basis.
−Removed: Our consolidated balance sheets as of December 31, 2015, and our consolidated statements of operations, comprehensive income (loss), and cash flows for the years ended December 31, 2016, and 2015, respectively, have been prepared on a “carve out” basis for the periods and dates prior to the Separation.
+Added: Our consolidated balance sheets as of December 31, 2020, 2019, 2018, 2017, and 2016, respectively, and our consolidated statements of operations, comprehensive income (loss), and cash flows for the years ended December 31, 2020, 2019, 2018, and 2017, respectively, consist of the consolidated balances of Ingevity as prepared on a stand-alone basis.
+Added: Our consolidated statements of operations, comprehensive income (loss), and cash flows for the year ended December 31, 2016 have been prepared on a “carve out” basis for the periods and dates prior to the Separation.
The selected consolidated financial data should be read in conjunction with our consolidated financial statements included within Part II.
2 unchanged sentences
In millions, except per share and share data 2020 2019 2018 2017 2016
−Removed: Statement of Operations Data:
+Added: Statements of Operations Data:
Net sales $ 1,216.1 $ 1,292.9 $ 1,133.6 $ 972.4 $ 908.3
Gross profit 465.5 482.0 416.8 329.0 274.4
−Removed: Income before income taxes 227.9 221.8 174.8 87.0 136.5
+Added: Income (loss) before income taxes 235.1 227.9 221.8 174.8 87.0
Net income (loss) attributable to Ingevity stockholders 181.4 183.7 169.1 126.5 35.2
15 unchanged sentences
_______________
−Removed: (1) On May 15, 2016, WestRock Company distributed 42.1 million shares of Ingevity's common stock to holders of its common stock.
−Removed: Basic and diluted earnings (loss) per share for the year ended December 31, 2015 is calculated using the number of common shares distributed on May 15, 2016.
−Removed: Basic and diluted earnings (loss) per share for the year ended December 31, 2016 is calculated using the weighted average number of common shares outstanding for the period beginning after May 15, 2016.
+Added: (1) Basic and diluted earnings (loss) per share for the year ended December 31, 2016 is calculated using the weighted average number of common shares outstanding for the period beginning after May 15, 2016, the date of Separation.
(2) Defined as current assets less current liabilities.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.